Clinical Trial Detail

NCT ID	NCT03674411
Title	Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Masonic Cancer Center, University of Minnesota
Indications	Hodgkin's lymphoma acute lymphoblastic leukemia acute myeloid leukemia acute promyelocytic leukemia peripheral T-cell lymphoma myelodysplastic syndrome mantle cell lymphoma chronic myeloid leukemia Burkitt lymphoma anaplastic large cell lymphoma
Therapies	Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus
Age Groups:	adult child